AZ reports additional Phase III Lynparza data in breast cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) reported additional data from the Phase III OlympiAD trial in 302 breast cancer patients showing that oral Lynparza olaparib (AZD2281, KU-0059436) as third-line or earlier treatment led to a median progression-free survival (PFS) as measured by blinded independent central review, the primary endpoint, of 7 months vs. 4.2 months for chemotherapy (HR=0.58, 95% CI: 0.43, 0.8, p=0.0009). Lynparza led to an objective response rate (ORR) of 59.9% vs. 28.8% for chemotherapy. Data were presented at the American Society of Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine.

The open-label, international trial enrolled patients with HER2-negative metastatic breast cancer with germline breast cancer 1 early onset (BRCA1) or BRCA2 mutations to receive twice-daily 300 mg Lynparza or physician's choice of capecitabine, vinorelbine or eribulin. Secondary endpoints in the trial include overall survival (OS), time to second progression or death (PFS2), ORR, health-related quality of life (QOL) and safety...